Enveric net loss narrows to $3 million in Q2 FY26; loss per share improves to $0.76

Reuters2026/08/14 20:06

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Enveric Biosciences posted a net loss attributable to stockholders of $3 million, or $0.76 per share, for Q2 ended June 30, 2026.
Loss per share narrowed from $11.65 a year earlier; net non-cash expense fell to $300,000 from $500,000.
Cash on hand totaled $8.3 million at quarter-end; raised $5 million in gross proceeds in offerings and $1.5 million from warrant exercises.
Advanced IND-enabling work for EB-003, initiating genotoxicity studies ahead of a planned IND submission and expected Phase 1 start.
CEO Joseph Tucker cited new preclinical data supporting EB-003’s non-hallucinogenic profile, including GloSensor assay results complementing prior BRET findings.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enveric Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608141605BIZWIRE_USPR_____20260814_BW007152) on August 14, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Enveric net loss narrows to $3 million in Q2 FY26; loss per share improves to $0.76

You may also like

Crypto prices